Leukocytosis and Natural Killer Cell Function Parallel Neurobehavioral Fatigue Induced by 64 Hours of Sleep Deprivation

David F. Dinges,*† Steven D. Douglas,*† Line Zaugg,* Donald E. Campbell,** Joseph M. McMann,† Wayne G. Whitehouse,* Emily Carota Orne,*† Shiv C. Kapoor,† Edward Iacza,* and Martin T. Orne*†

*Unit for Experimental Psychiatry, The Institute of Pennsylvania Hospital, Philadelphia, Pennsylvania 19139; †Department of Psychiatry, and ‡Division of Allergy-Immunology-Infectious Diseases, Department of Pediatrics, University of Pennsylvania School of Medicine; §Clinical Immunology Laboratory, Childrens Hospital of Philadelphia; ¶CRC Laboratory, Hospital of the University of Pennsylvania; and Center for Sleep and Respiratory Neurobiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

Abstract

The hypothesis that sleep deprivation depresses immune function was tested in 20 adults, selected on the basis of their normal blood chemistry, monitored in a laboratory for 7 d, and kept awake for 64 h. At 2200 h each day measurements were taken of total leukocytes (WBC), monocytes, granulocytes, lymphocytes, eosinophils, erythrocytes (RBC), B and T lymphocyte subsets, activated T cells, and natural killer (NK) subpopulations (CD56/CD8 dual-positive cells, CD16-positive cells, CD57-positive cells). Functional tests included NK cytotoxicity, lymphocyte stimulation with mitogens, and DNA analysis of cell cycle. Sleep loss was associated with leukocytosis and increased NK cell activity. At the maximum sleep deprivation, increases were observed in counts of WBC, granulocytes, monocytes, NK activity, and the proportion of lymphocytes in the S phase of the cell cycle. Changes in monocyte counts correlated with changes in other immune parameters. Counts of CD4, CD16, CD56, and CD57 lymphocytes declined after one night without sleep, whereas CD56 and CD57 counts increased after two nights. No changes were observed in other lymphocyte counts, in proliferative responses to mitogens, or in plasma levels of cortisol or adrenocorticotropic hormone. The physiologic leukocytosis and NK activity increases during deprivation were eliminated by recovery sleep in a manner parallel to neurobehavioral function, suggesting that the immune alterations may be associated with biological pressure for sleep. (J. Clin. Invest. 1994;93:1930–1939.) Key words: sleep deprivation • natural killer activity • leukocytes • monocytes • fatigue

Introduction

Sleep loss, endemic in modern society (1), degrades neurobehavioral function (2) and is popularly believed to adversely affect immune function. Although sleep changes often accompany fever and systemic infection, including HIV infection (3), there are few experimental data on immune alterations from sleep deprivation. Limited studies in mice (4) and rats (5, 6) have failed to document consistent alterations of immune responses during sleep loss, although death occurred in rats deprived of sleep for 7–32 d (6).

Human studies of sleep deprivation are rare, but they do not have the problem of stressor-induced forced wakefulness required in animal experiments. In 1976, Palmblad and colleagues (7) reported increased interferon production and decreased in vitro phagocytic activity of heparinized blood incubated with Staphylococcus albus after 77 h of wakefulness by 8 women. In a subsequent study of 12 men kept awake for 48 h, they reported decreased lymphocyte proliferation induced by PHA, but no changes in granulocyte adherence to nylon fibers or in granulocyte alkaline phosphatase activity (8). More recently, Moldofsky and colleagues (9) reported that 10 men sleep deprived for 40 h had elevated nocturnal levels of IL-1 and IL-2–like activity, a delayed nocturnal rise in lymphocyte proliferation to pokeweed mitogen (PWM), but no change in intravital natural killer cell (NK) activity. In a later study of 6 men deprived for 64 h, they replicated the delayed nocturnal rise in lymphocyte proliferation to PWM, and reported increased NK activity during the early evening hours (10).

Although intriguing, the human studies are limited by small numbers of immune variables and subjects, by the presence of other stressors during sleep loss, and by the absence of data on moderating variables (e.g., body temperature). It is unclear whether sleep deprivation decreases immune function, and whether immune alterations during sleep loss are associated with a stress response or biological pressure for sleep as reflected in neurobehavioral changes during sleep loss. These questions were addressed in an experiment in which immune function, plasma glucocorticoids, and neurobehavioral variables were evaluated in 20 healthy adults who remained awake for 64 h during 7 d of continuous in-lab monitoring.

Methods

Subjects

A total of 224 female and male young adult volunteers were screened to identify an eligible subset of 20 (7 females, 13 males, 21–30 y) who met the following criteria: healthy and free of active infection and symptoms; within normal limits on all parameters in one or more prestudy complete blood cell counts (CBC) and clinical chemistry tests; medication free (including females not using birth control pills); no medical history of cancer, hepatitis, or other serious conditions, including autoimmune disorders; within age-appropriate normal limits in physical and psychological health, sleep-wake pattern, and ease of blood draw.

1. Abbreviations used in this paper: CBC, complete blood cell count; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin content; MCV, mean corpuscular volume; NK, natural killer; PE, phycoerythrin; PWM, pokeweed mitogen; TC, target cell.
Sleep deprivation protocol

The experimental protocol required subjects to live around-the-clock for seven consecutive days (151 h), under constant supervision, in a comfortable laboratory environment devoid of explicit time cues and in which temperature (68°F), light (169 lux), and other environmental factors were held constant. During the first 2 d subjects were allowed to sleep at night while being monitored polysomnographically. For the next 3 d, subjects remained continuously awake for 64 h. Recovery sleep was allowed on nights 5 and 6.

Throughout all wake periods, the following data were obtained: continuous recordings of body motility and light exposure using Actilumes (Ambulatory Monitoring, Inc., Ardsley, NY); continuous recordings of electroencephalogram and electrooculogram with Medilog 9000 (Oxford Instruments, Clearwater, FL); hourly recordings of sublingual temperature; cognitive performance, mood, and sleepiness every 2 h; fluid intake and voiding; physical and psychological complaints; and continuous observation of behavior and health. Specially trained staff were with subjects at all times to encourage and help them remain awake by mild social activity, and when necessary, by ambulation. Nutritional balanced meals were provided throughout the protocol at appropriate times for breakfast, lunch, and dinner, and during sleep deprivation a late night snack was provided (caffeinated beverages were prohibited at all times). Subjects were paid $600 at the completion of the experiment, which they understood they could withdraw from at any time without jeopardy; no subject withdrew from the study or had to be withdrawn for an adverse reaction. The protocol was approved by the Human Subjects Committee of the Pennsylvania Hospital.

In vitro assays

Blood samples. Fig. 1 schematically presents the timing of blood draws in the protocol. Blood samples were collected at 2200–2230 h on the predeprivation baseline (B15) day, on each of the deprivation (SD15, SD39, SD63) days, and on the first recovery (R15) day (for logistic reasons waking blood draws before and after these 5 d were taken at 2100 h). (During these 5 d blood was also taken at 0100–0130 h, when subjects slept during baseline and recovery nights, and during wakefulness on deprivation nights; these sleep-wake results are not reported.) In all cases, blood was drawn by venipuncture from the antecubital fossa. At each of the 13 blood draws two 20-ml blood samples per subject were collected in a heparinized (preservative free) (lymphMed, Inc., Rosemont, IL) syringe and in an anticoagulant-free syringe. For the 2200–2300 h wake blood draws reported here, subjects were in a sitting position. 2 ml of the heparinized blood were removed for lymphocyte phenotype analysis, the remainder was used for measurement of NK activity, mitogen stimulation, and DNA analysis. The anticoagulant-free blood was immediately transferred into a 10-ml red cap vacutainer tube (Becton Dickinson Vacutainer Systems, Rutherford, NJ) for serum studies and two 5-ml lavender cap tubes containing 0.05-mL of 15% EDTA (K<sub>3</sub>) solution (7.5 mg) one for CBC and one for plasma assessment. All assays were performed by laboratory personnel blind to the identity of the samples.

CBC. CBC (WBC, granulocytes, monocytes, RBC, platelet count, hemoglobin, hematocrit, mean corpuscular volume [MCV], mean corpuscular hemoglobin [MCH], mean corpuscular hemoglobin content [MCHC], and differential) were performed using standard methods (STKA, Coulter Corp., Hialeah, FL) by an independent clinical laboratory (Damon Clinical Laboratories, Trevose, PA). CBC were performed on 90% of samples in < 6 h (maximum 12 h). WBC counts were also determined on site as a quality control check.

Lymphocyte preparation and distribution. PBMC were obtained using a Ficoll-Paque gradient (Pharmacia Biotechnology Inc., Piscataway, NJ) (11). Cells were washed twice with PBS (Gibco Life Technologies Inc., Grand Island, NY) and resuspended in RPMI medium (Cellgro, Mediatech, Washington, DC) enriched with 15% normal human serum (Gibco) (inactivated 1 h in a 56°C water bath) and 100 U/ml of penicillin (Gibco), 100 μg/ml of streptomycin (Gibco), and 0.29 mg/ml of l-glutamine (Gibco). The cell suspension was adjusted to 1 x 10⁷ cells/ml for NK activity assessment and to 1 x 10⁵ cells/ml for mitogen-stimulated cultures and DNA analysis. Cell viability was > 98% (tested by Trypan Blue, Gibco).

Cell phenotyping and enumeration. Flow cytometry was used to enumerate subpopulations of B cells (CD20) and the following T cells: T helper (CD4) and T suppressor (CD8) cells, inducer-helper (CD29) and inducer-suppressor (CD45RA) cells, and activated T cells (HLA-DR receptor). NK cell numbers were analyzed using three different mAbs (CD56, CD57, CD16), in an effort to identify all NK-related cells. CD56 cells were enumerated by a dual-color mAb that stained positively for CD8. Enumerations of CD57 and CD16 phenotypes were added as the experiment progressed and were accomplished by single-color markers, respectively. As summarized in Table I, lymphocyte phenotyping was performed with mAbs from Coulter Corp. and from Becton Dickinson (Immunocytometry Division, San Jose, CA) (12). All mAbs were directly conjugated with FITC or phycoerythrin (PE). 100 μl of heparinized blood was added to 10 μl of mAbs. Coulter Corp. methodology was performed to prepare the samples; 30 min of incubation was used for whole blood and antibodies. Analysis was performed with an EPICS Profile II flow cytometer (Coulter Corp.).

Mitogen-induced lymphocyte stimulation. PBMC were cultured with PHA (Wellcome Diagnostics, Dartford, England), ConA (Sigma Chemical Co., St. Louis, MO), and PWM (Gibco) (13). 100 μl of PBMC suspension (1 x 10⁶ cells/ml) was cultured in triplicate in flat-bottom 96-well plates (Fisher Scientific Co., Malvern, PA) with 100 μl of mitogen. Mitogen concentrations were used that yielded the optimal response: 1 μg/ml for PHA, 30 μg/ml for ConA, and 1 μg/ml for PWM. The plates were incubated at 37°C and 5% CO₂ for 70 h (PHA and ConA) and for 118 h (PWM). 1 μCi/well of [³H]thymidine (ICN BioMedical Inc., Irvine, CA) was added for 20 h before harvesting on fiberglass paper (cell harvester, Brandel Biomedical, Inc., Gaithersburg, MD). The samples were counted in a liquid scintillation counter (Wallac Oy, Turku, Finland), and the data were expressed as counts per minute of stimulated culture minus the counts per minute of unstimulated culture.

NK cell activity. NK activity was assessed utilizing a modification (14, 15) of standard techniques. The cell line K-562 was used as the target cell (TC). Cells were maintained in a RPMI 1640 medium enriched with 10% FCS (Gibco) (inactivated 1 h in a 56°C water bath) and 100 U/ml of penicillin (Gibco), 100 μg/ml of streptomycin (Gibco) and 0.29 mg/ml of L-glutamine (Gibco). TC were washed twice with the media and resuspended in 1 ml, after which they were incubated with 0.5 ml of Na<sub>3</sub>CrO<sub>4</sub> (60Cr; Dupont NEN, Boston, MA) at 37°C and 5% CO₂ for 2 h. After incubation TC were washed twice and ad-

---

**Figure 1.** Schematic time line of sleep deprivation protocol, showing periods of nocturnal sleep (black bars) and times of blood draws (downward arrows) between 2200 and 2230 h on each of five consecutive days (predeprivation baseline [B15], day 1 of deprivation [SD15], day 2 of deprivation [SD39], day 3 of deprivation [SD63], and the first day after recovery sleep [R15]). Results are not reported here for blood draws designated by smaller arrows (taken 3 d before and following the experimental phase, as well as at 0100–0130 h each day, and at 2100 h on the last day of the protocol).
Table I. Monoclonal Antibodies Used for Lymphocyte Phenytoping

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Monoclonal antibody</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monocyte/Pan leukocyte</td>
<td>CD14-PE/CD45-FITC</td>
<td>Coulter</td>
</tr>
<tr>
<td>Pan T cells (E-rosette)/Pan B cells</td>
<td>CD22-PE/CD20-FITC</td>
<td>Coulter</td>
</tr>
<tr>
<td>Inducer T cells/suppressor/cytotoxic T cells</td>
<td>CD4-PE/CD8-FITC</td>
<td>Coulter</td>
</tr>
<tr>
<td>Helper-inducer subset/inducer T cells</td>
<td>CD29-PE/CD4-FITC</td>
<td>Coulter</td>
</tr>
<tr>
<td>Suppressor-inducer subset/inducer T cells</td>
<td>CD45RA-PE/CD4-FITC</td>
<td>Coulter</td>
</tr>
<tr>
<td>Natural killer cells/suppressor/cytotoxic T cells</td>
<td>CD56-PE/CD8-FITC</td>
<td>Coulter</td>
</tr>
<tr>
<td>Immunocompetent T cells/activated T and B cells, monocytes</td>
<td>CD3-PE/34, 29Kd-FITC (CD No. not assigned)</td>
<td>Coulter</td>
</tr>
<tr>
<td>NK cells</td>
<td>CD57-FITC</td>
<td>Becton Dickinson</td>
</tr>
<tr>
<td>NK cells</td>
<td>CD16-FITC</td>
<td>Becton Dickinson</td>
</tr>
</tbody>
</table>

Control monoclonal antibody

Mouse IgG1-PE/Mouse IgG1-FITC | Coulter |
Mouse IgG1-PE/Mouse IgG2-FITC | Coulter |
Mouse Ig-M-FITC | Coulter |

justed to 1 × 10⁵ cell/ml; cell viability was > 96% (tested with Trypan Blue). After 100 µl of 1 × 10⁵ PBMC/ml were incubated in triplicate with 100 µl of labeled target cells for 4 h at 37°C and 5% CO₂ (effector/target ratio was 100:1), 100 µl of the supernatants was harvested and counted in a gamma counter (Beckman Instruments Inc., Fullerton, CA). NK activity was calculated as ([sample activity - spontaneous release]/[total release - spontaneous release]) × 100. Total release of ⁵¹Cr was done with 100 µl of a 5% Triton solution and the TC. Spontaneous release was performed with 100 µl of media and the TC. Results were expressed in percent specific cytotoxicity.

**DNA analysis.** Flow cytometry was used to quantitate the proportion of PBMC in each phase of the cell cycle, to provide an additional sensitive measure of lymphocyte mitogenic events (16). 500 µl of PBMC (1 × 10⁶ cells/ml) were incubated with 500 µl of PHA (1 µl/ml) for 22, 46, and 70 h, and with 500 µl of RPMI medium (prepared as described above) for 0 and 70 h. After incubation at 37°C and 5% CO₂, the supernatants were aspirated, leaving the cell pellets. The cell pellets were resuspended and fixed with 70% ethanol (Mallinkrodt Inc., Paris, KY), then washed twice with 2 ml of PBS, and 0.5 ml of 3% propidium iodide (Sigma Chemical Co.) was added. They were then incubated at 4°C for 60 min. The samples were then analyzed using an EPICS Profile II flow cytometer for determination of the fluorescence intensity of each cell, which is directly proportional to the amount of DNA in the nucleus of the cell. All histograms were transferred to the networked computer for cell cycle analysis (Multicycle, Phoenix Flow System, San Diego, CA). The results were expressed as the relative percentages of cells in each of the cell cycle phases: (G₀/G₁ = pre-DNA synthesis phase; S = DNA synthesis phase; and G₂ = post-DNA synthesis phase).

**Glucocorticoid assays.** To determine the extent to which sleep deprivation activated the hypothalamic-pituitary-adrenal axis, plasma levels of cortisol and ACTH from frozen serum (~70°C) were evaluated throughout the protocol in 12 subjects by standard RIA kits (Diagnostic Products Corp., Los Angeles, CA).

**Data analyses**

One-way analysis of variance corrected for sphericity using Greenhouse-Geisser epsilon was used to evaluate whether there was a statistically significant (P ≤ 0.05) variation in each dependent variable across 5 d: from baseline (B15) through 3 d without sleep (SD15, SD39, SD63) and after a recovery night of sleep (R15). For significant F ratios, single degree-of-freedom polynomial tests of order were conducted to determine the presence of significant linear, quadratic, cubic, and fourth-order profiles in the data, and critical difference comparisons were carried out among means using Newman-Keuls’ Critical Difference Test. Spearman rank order correlations (P ≤ 0.05, two-tailed criteria) were used to determine whether change scores (not normally distributed) across sleep-deprivation days (SD63 minus SD15) were correlated with change scores in other immune parameters that varied significantly across days. Additional analyses on the effects of recovery sleep were conducted using dependent t tests (two-tailed criteria).

**Results**

**Clinical examinations.** Twice daily exams (one by a nurse and one by a physician) revealed no signs or symptoms of viral or bacterial infection in subjects, and no febrile responses were obtained on any of the sublingual temperature recordings taken on each subject every 2 h throughout the waking portions of the protocol. There was no systematic evidence of viral or bacterial infection (e.g., upper respiratory illness) in subjects at an evaluation 3 d after the protocol, as well as in daily logs completed by subjects for 9 d after the study.

**Neurobehavioral measures.** The sleep deprivation manipulation had the expected adverse effects on neurobehavioral outcomes. Fig. 2 displays data for two sleepiness (top panel) and cognitive performance (second panel) obtained every 2 h throughout all waking periods of the protocol. The panels show only the results obtained at the 2200-h tests each day, which took place within a few minutes of the 2200-h blood draws. As is evident in the top panel of Fig. 2, sleepiness ratings as measured by the Stanford Sleepiness Scale (17) increased across days of sleep deprivation, and declined after a night of recovery sleep (F₁₈,₇₆ = 18.4, P = 0.0001). The polynomial profile for these ratings contained significant quadratic (P = 0.0001) and cubic (P = 0.0001) components. Similar results were found for fatigue ratings from analog scales and adjective checklists completed throughout the protocol.

A comparable pattern seen in the second panel of Fig. 2 was obtained for vigilance lapses on a sustained-attention reaction time performance task that is well documented to be sensitive to sleep loss (18-20). Lapses (reaction times ≥ 500 ms) increased with consecutive days of sleep loss and were reduced after recovery sleep (F₁₈,₇₆ = 48.1, P = 0.00001). The profile included significant linear (P = 0.0001), quadratic (P
In contrast to neurobehavioral variables, body temperature and body motility immediately before blood draws at 2200 h (see bottom two panels of Fig. 2) did not show significant variation between days. Body temperature, assessed sublingually, was comparable across days at the time blood was taken ($F_{4,76} = 1.8$). Body motility, assessed actigraphically, also showed no reliable variation for the values from 2200–2300 h across days of sleep deprivation and recovery ($F_{4,72} = 1.6$). Both body temperature and to a lesser extent, body motility, showed robust circadian (within-a-day) variation, as did the neurobehavioral outcomes. The pattern of results presented in Fig. 2 suggests circadian rhythms during sleep loss did not yield significant differences in body temperature or motility at 2200 h each day. This was confirmed by visual inspection of circadian body temperature curves, which suggested that the 2200-h blood draws occurred at the same circadian phase each day.

**CBC and cell phenotype enumeration.** RBC counts decreased across consecutive days of the study ($F_{4,76} = 13.9, P = 0.0001$) in a manner consistent with hemodilution. The decreases were linear ($P = 0.0001$) and of relatively small magnitude (highest count on B15, $M = 4.967 \times 10^6$/mm$^3$; lowest count on R15, $M = 4.741 \times 10^6$/mm$^3$; difference = 4.5%). Hemoglobin ($F_{4,76} = 10.4, P = 0.0001$), hematocrit ($F_{4,76} = 13.8, P = 0.0001$), and MCV ($F_{4,76} = 5.7, P = 0.002$) paralleled the linear declines in RBC counts across days, but no systematic variation was observed for platelet count, MCH, or MCHC.

Total WBC counts increased across days of sleep loss and partially returned to predeprivation levels after recovery sleep ($F_{4,76} = 5.9, P = 0.002$), reflecting both linear ($P = 0.01$) and 4th-order ($P = 0.002$) polynomial components. There was an increase of 12.7% from predeprivation (B15, $M = 7.38 \times 10^3$/mm$^3$) to maximum deprivation (SD63, $M = 8.32 \times 10^3$/mm$^3$). Significant increases during deprivation were also observed for the numbers of granulocytes ($F_{4,76} = 7.3, P = 0.001$) and monocytes ($F_{4,76} = 8.4, P = 0.0005$), but not for the numbers of lymphocytes ($F_{4,76} = 2.1$) or eosinophils ($F_{4,76} = 1.7$). Results for granulocytes, lymphocytes, and monocytes are shown in Fig. 3. The profile for granulocyte numbers contained linear ($P = 0.001$), cubic ($P = 0.037$), and 4th-order ($P = 0.014$) components. Similarly, the profile for monocyte counts contained linear ($P = 0.001$) and cubic ($P = 0.017$) components. The increase in mean values across deprivation (from B15 to SD63) was 22.6% for granulocyte numbers and 22.7% for monocyte counts.

Consistent with a lack of change in total lymphocyte counts, there were no statistically significant effects over time found for the numbers of B lymphocytes ($F_{4,76} = 1.3$) and T lymphocytes ($F_{4,76} = 2.1$). The enumeration of T cell subsets of deprivation after 63 h awake (SD63), and the first day after recovery sleep after 15 h awake (R15). Data from days on which sleep was deprived are designated by open circles (SD15, SD39, SD63). Horizontal lines show the results of critical difference comparisons (Newman-Keuls’ Tests) carried out among means for those variables in which a statistically significant $F$-ratio was obtained from analysis of variance across days. Means that differ significantly have a horizontal line in common, with the significance level of the difference shown at one end of the line.
NIK cell counts showed systematic variation across days for CD56 (F_{4.36} = 4.9, P = 0.005), CD57 (F_{4.44} = 3.8, P = 0.049), and CD16 (F_{4.12} = 7.7, P = 0.047) subsets. The bottom panels of Fig. 4 display the results for CD56 and CD57. In both cases the data were best characterized by a 4th-order polynomial profile (CD56, P = 0.0001; CD57, P = 0.001). Newman-Keuls' comparisons between means revealed significant increases (P = 0.05) from SD39 to SD63 in CD56 counts (28.8%) and CD57 counts (33.6%), and significant increases between SD39 and R15 (CD56 = 34.9%; CD57 = 35.6%). The apparent decreases in CD56 counts and CD57 counts from predeprivation (SD15) to after a night without sleep (SD39) were not significant by Newman-Keuls' tests, but were significant by dependent t test comparisons for both CD56 (t = 2.47, n = 19, P = 0.023) and CD57 counts (t = 2.64, n = 11, P = 0.023). However, this decrease across the first night without sleep was significant (P = 0.01) by Newman-Keuls' test for CD16 cell counts (32.0%) for the four subjects on which data were available. The decrease appeared to be the result of the value at SD15 being significantly above CD16 counts on all other days, including baseline (Newman-Keuls' tests). Unlike CD56 and CD57 counts, however, CD16 counts remained lower at maximum deprivation (SD63) and increased after recovery (R15). These latter changes were not significant by Newman-Keuls' comparisons, but they reached the 0.05 level for more liberal dependent t tests.

**NK cell activity.** Results for NK activity are shown in the top panel in Fig. 4. NK activity varied significantly across days (F_{4.76} = 9.7, P = 0.0005); there was a 13.9% increase in cytotoxicity from predeprivation (B15) to maximum deprivation (SD63). Similar to vigilance lapses (Fig. 1), all polynomial tests were significant for NK activity: linear (P = 0.0001), quadratic (P = 0.027), cubic (P = 0.024), and 4th-order (P = 0.042) profiles. Newman-Keuls' tests among means revealed that NK activity at SD63 was significantly greater than NK activity at all other time points, a result also obtained for subjective sleepiness, vigilance lapses (Fig. 2), and monocyte counts (Fig. 3).

**Lymphocyte proliferation.** In vitro lymphocyte proliferative responses to PHA, ConA, and PWM showed little systematic variation across days. Nonsignificant outcomes were obtained for lymphocyte responses to ConA after 70 h of incubation (F_{4.76} = 2.4), for PWM after 46 h of incubation (F_{4.72} = 1.4), and for PHA after 24 h (F_{4.71} = 1.3) and 70 h (F_{4.72} = 1.2) of incubation. There was significant variation across days in response to PHA at 48 h of incubation (F_{4.84} = 4.9, P = 0.024), but this effect was due to a drop in proliferative response between B15 and all subsequent time points, including SD15, which was equal to B15 in wake time.

**DNA analyses.** Although lymphocyte proliferative responses appeared unaffected by sleep loss, analysis of DNA to quantitate the proportion of lymphocytes in each phase of the cell cycle revealed some significant changes with sleep loss. Significant effects were found for DNA analysis of lymphocytes incubated in PHA for 22, 46, and 70 h. Incubation for 22 h resulted in no changes in cell percentages in G0/G1 phase (F_{4.60} = 2.1) or G2 phase (F_{4.60} = 2.3), but there was a significant increase in the proportion of cells in S phase as sleep loss progressed (F_{4.60} = 2.9, P = 0.044), following a linear (P = 0.004) profile. Results for 46 h of incubation were negative for cell percentages in the G2/G1 phase (F_{4.76} = 2.5), G2 phase (F_{4.76} = 2.6), and S phase (F_{4.76} = 0.9). However, at 70 h incubation in PHA, sleep loss affected the proportion of cells in each phase.

---

![Figure 3. Means (SEM) for granulocyte counts, lymphocyte counts, and monocyte counts from 20 healthy young adults. See Fig. 2 for explanation of graph.](image-url)
NATURAL KILLER ACTIVITY

0.05
0.01
0.01
0.05
0.05
0.01

G1/G0 phase \((F_{4,72} = 1.7)\), G2 phase \((F_{4,72} = 0.5)\), or S phase \((F_{4,72} = 2.0)\). At 70 h of incubation, however, there were significant decreases across deprivation in the percentage of cells in G1/G0 phase \((F_{4,76} = 12.7, P = 0.0005)\), and significant increases in the percentage of cells in S phase \((F_{4,76} = 12.8, P = 0.0005)\). The S phase profile reflected both quadratic \((P = 0.0001)\) and cubic \((P = 0.032)\) components. Results for S phase at 0 and 70 h of incubation in RPMI are shown in the bottom two panels of Fig. 5.

Glucocorticoid analyses. Plasma levels of cortisol varied systematically across deprivation \((F_{4,44} = 3.8, P = 0.022)\) with both linear \((P = 0.032)\) and quadratic \((P = 0.041)\) components. However, the pattern was not associated with sleep deprivation. Instead, cortisol levels were higher on baseline \((B1)\) and recovery \((RI)\) days than on any sleep deprivation day. The

Figure 4. Means (SEM) for NK cell activity, and counts of CD56 and CD57 cells from 20 healthy young adults. See Fig. 2 for explanation of graph.

of the cell cycle: decreasing the percentage in G1/G0 \((F_{4,76} = 2.8, P = 0.048)\) in a linear manner \((P = 0.035)\); increasing the percentage in G2 \((F_{4,76} = 3.6, P = 0.023)\) (significant quadratic and 4th-order profile); and increasing the proportion in S phase \((F_{4,76} = 6.5, P = 0.001)\) in a profile with linear \((P = 0.002)\) and quadratic \((P = 0.019)\) components. Results for S phase cell percentages after 70 h of incubation in PHA are shown in the top panel of Fig. 5.

No systematic variation over time was found at 0 h of incubation in RPMI control medium for percentages of cells in

Figure 5. Means (SEM) for the proportion of lymphocytes in the S phase of the cell cycle after 70 h of incubation with PHA, 70 h incubation in control medium (RPMI), and 0 h of incubation in control medium (RPMI). See Fig. 2 for explanation of graph.
Table II. Spearman Correlation Coefficients between \( n = 20 \) Change Scores (SD63 to SD15) in Immune Parameters across Sleep Deprivation

<table>
<thead>
<tr>
<th></th>
<th>Granulocytes</th>
<th>Monocytes</th>
<th>NK (CD56)</th>
<th>NK activity</th>
<th>RPMI(70 h)</th>
<th>PHA(70 h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC</td>
<td>0.897*</td>
<td>0.743*</td>
<td>0.503()</td>
<td>0.213</td>
<td>0.224</td>
<td>-0.386()</td>
</tr>
<tr>
<td>Granulocytes</td>
<td></td>
<td>0.505()</td>
<td>()</td>
<td>0.389()</td>
<td>0.135</td>
<td>-0.258</td>
</tr>
<tr>
<td>Monocytes</td>
<td></td>
<td></td>
<td>()</td>
<td>0.408()</td>
<td>0.435()</td>
<td>-0.538()</td>
</tr>
<tr>
<td>NK (CD56)</td>
<td></td>
<td></td>
<td></td>
<td>()</td>
<td>0.005</td>
<td>()</td>
</tr>
<tr>
<td>NK activity</td>
<td></td>
<td></td>
<td></td>
<td>()</td>
<td>0.245</td>
<td>()</td>
</tr>
<tr>
<td>RPMI (70 h) S phase</td>
<td></td>
<td></td>
<td></td>
<td>()</td>
<td>-0.220</td>
<td>-0.443()</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.274</td>
</tr>
</tbody>
</table>

\* \( P < 0.01 \); \^ \( P < 0.05 \); \^\^ \( P = 0.06-0.10 \).

Changes in the proportion of lymphocytes in the S phase after 70 h of incubation in RPMI control medium were not correlated with changes in other immune parameters affected by sleep loss.

**Effects of recovery sleep.** Dependent \( t \) tests were conducted to provide more detailed information on the extent to which recovery sleep had two effects: (a) change from maximum sleep loss (i.e., SD63 to R15); and (b) return to predeprivation levels (i.e., SD15 to R15). Table III displays the results of dependent \( t \) tests between SD63 and R15, and SD15 and R15; for comparison, the effects of sleep deprivation from SD15 to SD63 are also shown. Immune variables listed in Table III include only those for which a statistically significant change from SD15 to SD63 was observed by dependent \( t \) test.

Recovery sleep resulted in a reversal of sleepiness and performance failures as reflected in neurobehavioral measures (Fig. 2). Subjective sleepiness ratings showed full recovery, declining from SD63 to R15 (\( t = 7.84, P = 0.0001 \)) to a level indicative of slightly less sleepiness at R15 relative to predeprivation at SD15 (\( t = 2.14, P = 0.045 \)). Vigilance performance lapses showed nearly full recovery, declining from SD63 to R15 (\( t = 7.32, P = 0.0001 \)), while remaining slightly but significantly above the predeprivation SD15 level (\( t = -2.62, P = 0.017 \)). The difference between subjective sleepiness and performance lapses after recovery, relative to their respective predeprivation levels, is often observed in sleep deprivation studies; performance recovery lags temporally relative to self-estimates of sleepiness.

NK activity showed full recovery (Fig. 4), being significantly reduced at R15 relative to SD63 (\( t = 2.41, P = 0.026 \)), resulting in no statistically significant difference in NK activity between predeprivation and recovery levels (\( t = -1.50 \)). Monocyte counts (Fig. 3) also showed nearly complete recovery, being significantly reduced from SD63 to R15 (\( t = 3.28, P = 0.004 \)), which resulted in only a marginal elevation above the SD15 predeprivation level (\( t = -1.88, P = 0.075 \)). Less complete recovery was seen for WBC and granulocyte counts (Fig. 3). Both showed nonsignificant declines from SD63 to R15, but enough subjects declined to also yield no significant difference with the SD15 predeprivation average.

Cell cycle percentages from analysis of lymphocyte DNA after 70 h of incubation in PHA showed no change from SD63 to R15. The proportion of cells in the prereplication phase \( G_0/G_1 \) was unchanged at R15 relative to maximum sleep loss (\( t = -0.39 \)), remaining significantly below the SD15 predeprivation mean (\( t = 2.80, P = 0.011 \)). As evidenced in the top panel of Fig. 5, recovery sleep not only did not reverse the increased
Table III. Summary of Dependent t Test Results on the Extent to Which Recovery Sleep Reversed the Effects of Sleep Loss

<table>
<thead>
<tr>
<th></th>
<th>(SD15 to SD63)</th>
<th>(SD63 to R15)</th>
<th>(SD15 to R15)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurobehavioral measures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stanford Sleepiness</td>
<td>t (0.0002)</td>
<td>d (0.0001)</td>
<td>+ (0.045)</td>
</tr>
<tr>
<td>Vigilance lapses</td>
<td>+ (0.0001)</td>
<td>d (0.0001)</td>
<td>+ (0.017)</td>
</tr>
<tr>
<td>Phenotype enumeration</td>
<td>+ (0.012)</td>
<td>- (0.002)</td>
<td>- (0.075)</td>
</tr>
<tr>
<td>WBC</td>
<td>+ (0.001)</td>
<td>- (0.004)</td>
<td>- (0.075)</td>
</tr>
<tr>
<td>Monocytes</td>
<td>+ (0.0002)</td>
<td>- (0.026)</td>
<td>- (0.011)</td>
</tr>
<tr>
<td>NK cell activity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percent cytotoxicity</td>
<td>- (0.0009)</td>
<td>+ (0.002)</td>
<td>+ (0.0074)</td>
</tr>
<tr>
<td>DNA analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHA at 70 h: G0/G1 phase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHA at 70 h: S phase</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Arrow indicates direction of change (P = ).

The proportion of cells at SD63 in the S phase after 70 h of incubation in PHA, but there was a trend for further increase (3.1%) after recovery sleep (t = -1.88, P = 0.074), resulting in an average of 11% more cells in S phase at R15 than at predeprivation SD15 (t = -5.16, P = 0.0001).

The effects of R15 on cell cycle percentages for 70 h of incubation in RPMI control medium were not included in Table III because there were only marginal changes (0.05 < P > 0.11) in percentages from SD15 to SD63. Although the effect of sleep deprivation on cell cycle percentages from lymphocytes incubated in the control medium was modest, the effect of recovery sleep was robust, as seen in Fig. 5. The proportion of cells in S phase was reduced 11.5% from SD63 to R15 (t = 6.31, P = 0.0001), resulting in the percentage at R15 being significantly (P = 0.01) below all points except baseline.

Discussion

Acute sleep loss produced fatigue and cognitive performance failures in all subjects, consistent with its effects on brain function (2, 21). These neurobehavioral changes were paralleled by increases in peripheral blood counts of total WBC, granulocytes and monocytes, indicative of physiologic leukocytosis, and by increased NK activity. This pattern was strikingly consistent among subjects, regardless of gender, race, or time of year of study (e.g., 19/20 subjects had increased monocyte counts; 19/20 had increased NK activity). The increases ranged from 13% to 36% of predeprivation values for WBC, granulocytes, and monocytes, and 14% for NK activity. This is the first time such a pattern has been observed in healthy young adults deprived of sleep. Collectively these changes suggest activation of nonspecific immune parameters, rather than immune suppression.

The covariation of leukocytosis and NK activity with sleep loss and recovery sleep suggests that these aspects of immune function may be influenced by biological pressure for sleep. NK cells are large granular lymphocytes important for recognition and destruction of malignant and virally-infected cells; they can be cytotoxic for tumor cells without prior sensitization (22). The increase of NK activity during sleep loss contrasts with findings of NK activity decreases in adults exposed to acute behavioral stressors (23, 24), and in depressed patients (25). NK activity has recently been shown to be negatively correlated with subjective symptoms of insomnia (26-28), and positively correlated with polysomnographic measures of total sleep time, sleep efficiency, and non-REM sleep duration (29). Increases in each of these parameters is evidence of elevated sleep pressure (i.e., the tendency to sleep). Interestingly, we found that NK activity increased following two nights, but not one night, without sleep. This outcome is consistent with the results of Moldofsky et al. (9), who reported that 40 h of sleep loss had no clear effects on NK activity, but in a subsequent study found that 64 h without sleep elevated NK activity during the early evening hours (10). The lag in NK activity in response to sleep loss may reflect the transient decreases in NK cell counts we observed after the first night without sleep.

Monocytes may have played a key role in the immune response to sleep loss. The magnitude of the increases in monocyte counts across sleep deprivation positively correlated with increases in total WBC, granulocyte counts, and NK activity. Monocytes may have affected NK activity through secretion of cytokines. NK cells are activated by cytokines such as IL-1α, IFNγ, and IL-6; for example, IL-1α, which is secreted by monocytes, can activate NK cells both directly and indirectly via IFNγ (30). Cytokines have been implicated in the regulation of sleep, and in the response to sleep loss. Studies on rabbits and rats of intracerebroventricular administration of IL-1β, IFNγ, and TNFα have demonstrated that these proteins have somnogenic effects independent of their pyrogenic effects (31-33). In non-sleep-deprived humans, cytokines can be difficult to detect in plasma (34), but there is evidence of them in plasma during sleep deprivation. Palmblad et al. (7) found increased IFN production during and after 77 h of sleep loss. Moldofsky et al. (9) found that 40 h of sleep deprivation enhanced IL-1-like and IL-2-like activities.

Enumeration of B lymphocytes and most subsets of T cells showed no systematic changes across sleep deprivation, but there was evidence during the first 15-39 h without sleep for decreases of ~ 8% in CD4 counts, 17% in CD56 counts, 16% in CD57 counts, and 32% in CD16 counts. CD4 and CD16 counts remained reduced as sleep loss progressed to 63 h, while CD56 and CD57 counts increased. Although reduction of CD4, CD8, CD16, CD56, and CD57 cell percentages are among the most common findings reported in studies of human immune responses to various types of life stressors (35), decreases in these cell populations after the first night without sleep may not reflect a nonspecific stressor effect in our experiment. There was no behavioral or physiological evidence of distress following the first night without sleep. Subjects were not depressed, angry, anxious, or unhappy on the mood scale assessments. Plasma levels of cortisol and ACTH did not show evidence of hypothalamic-pituitary-adrenal activation, although receptor studies would be needed to resolve this issue further. By 63 h without sleep the neurobehavioral effects of sleep loss were greater than at 39 h, but there was still little evidence of distress from mood profiles, behavioral observations, or glucocorticoid levels. This raises the possibility that the observed transient decreases in lymphocyte counts after a single night without sleep reflect something other than distress, and that they may simply be an initial phase of a more complicated response leading to activation of immune responses rather than suppression. Distress reactions are not an inevita-
ble consequence of sleep deprivation in the laboratory. Other studies have also failed to find elevated plasma levels of glucocorticoids (2, 36, 37), even up to 205 h without sleep (38, 39). When elevations were observed, the experiments involved intensive physical (40) or mental (41) demands. Similarly, in rodent studies, plasma levels of corticosterone and ACTH were not elevated above levels for yoked controls until many days into the deprivation, proximal to fatality (42, 43). On the other hand, there was evidence early in deprivation of rats of elevated plasma norepinephrine. Although human sleep deprivation studies have not observed evidence of sympathetic nervous system alterations during sleep deprivation (2, 37, 38), we cannot rule out the possibility that catecholaminergic changes mediated some of the immune effects we observed during sleep loss.

DNA analyses were done to reflect changes in lymphocyte proliferative capacity. Sleep loss was associated with increases in the proportion of cells in S phase after incubation in PHA for 70 h, which is not consistent with the lack of increased total lymphocyte numbers or increased proliferative responses to PHA. There was no systematic elevation in S phase percentage until the maximum time of sleep loss, and there was no reduction after recovery sleep, resembling the pattern seen for CD56 and CD57 cell counts. It is not clear, however, that the DNA synthesis pattern and the pattern of lymphocyte counts share a common variance, since there were negative correlations between change in S-phase cell percentage and changes in both CD56 cell counts and monocyte counts across deprivation. Subjects with larger increments in monocyte counts during deprivation tended to have smaller increments in the proportion of cells in S phase, and vice versa. This finding suggests that the rise in monocytes accompanying sleep loss may be associated with concomitant inhibition of increases in lymphocytes. The process by which this could occur is unknown, since these phenomena are normally synergistic.

Finally, we note that despite neurobehavioral impairments, leukocytosis, and NK activation at 63 h without sleep, there was no clinical evidence of infectious illness either during, or up to 9 days after, sleep deprivation. It remains to be determined whether the changes observed in immune cell trafficking patterns during sleep deprivation occurred at a subclinical level or actively altered the vulnerability to infection. The findings support the hypothesis that sleep loss can alter immune function, but there was no immunologic or clinical evidence to support the hypothesis that these alterations are in the direction of immune decreases, and no psychological or glucocorticoid evidence to support the hypothesis that the immune changes resulted from a nonspecific stress response. However, given the disparity between the effects of one versus two nights without sleep on immune parameters, even more severe sleep loss may result in failure of immune function, as has been suggested may occur in the lethal outcome studies of rats deprived of sleep for many days (44). Our data indicate that acute loss of sleep to the point of impairment of neurobehavioral function in humans is associated with leukocytosis and increased NK cell counts and activity, and that these outcomes are reversed by recovery sleep.

Acknowledgments

For help in study planning, logistics, and data acquisition, we thank Dr. Steven E. Keller, Darcy L. Reber, Barbara A. Haupt, Andrea M. Laizner, Paul Ukpah, Kelly A. Gillen, John W. Powell, Michele M. Carlin, Dr. Nancy Barone Kribbs, Dr. Brad L. Bates, Dr. Jay Getsy, Dr. Joanne E. Getsy, Jeanne S. Schuett, John Henry, Kathleen M. Allen, Allison Cromwell, Amy R. Weeks, Angela D. Touhey, Peg Coley, Hans Hasinger, Dr. Laurie Kilpatrick, Dr. Andrew Winokur, Dr. Albert Lee, Dr. Larry Leventhal, and Dr. Mark R. Rosekind and NASA Ames Research Center.

This study was supported by grant MH-44193 from the National Institute of Mental Health, National Institutes of Health (NIH), and by the Institute for Experimental Psychiatric Research Foundation. Portions of the work were also supported by NIH grant CRC RR 00040, and grant NCC-2-599 from NASA.

References